相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics
Steven R. Feldman et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2019)
Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis
Jashin J. Wu et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
Drug survival of biologic treatments in psoriasis: a systematic review
Daniel J. No et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
Drug utilization patterns and adherence in patients on systemic medications for the treatment of psoriasis: A retrospective, comparative cohort study
Erica D. Dommasch et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence
Pei-Tzu Lin et al.
SCIENTIFIC REPORTS (2018)
Patient reported health outcomes and non-adherence in psoriasis patients receiving adalimumab or ustekinumab for moderate to severe plaque psoriasis
Amir Goren et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2016)
Patterns of Medication Utilization and Costs Associated with the Use of Etanercept, Adalimumab, and Ustekinumab in the Management of Moderate-to-Severe Psoriasis
Steven R. Feldman et al.
Journal of Managed Care & Specialty Pharmacy (2016)
Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry
J. Zweegers et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population
Jalpa A. Doshi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Economic Burden of Psoriasis in the United States A Systematic Review
Elizabeth A. Brezinski et al.
JAMA DERMATOLOGY (2015)
Ustekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasis
Zhun Cao et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2015)
Psoriasis prevalence among adults in the United States
Tara D. Rachakonda et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Eliciting Preferences to Inform Patient-Centred Policies: the Case of Psoriasis
Aleksandra Torbica et al.
PHARMACOECONOMICS (2014)
Psoriasis Severity and the Prevalence of Major Medical Comorbidity A Population-Based Study
Howa Yeung et al.
JAMA DERMATOLOGY (2013)
Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy
Elizabeth A. Brezinski et al.
PLOS ONE (2012)
Patient Preferences for Psoriasis Treatments Process Characteristics Can Outweigh Outcome Attributes
Marthe-Lisa Schaarschmidt et al.
ARCHIVES OF DERMATOLOGY (2011)
Epidemiology of comorbidities in psoriasis
Luigi Naldi et al.
DERMATOLOGIC THERAPY (2010)
Guidelines of care for the management of psoriasis and psoriatic arthritis Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004
Shanu Kohli Kurd et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
Guidelines of care for the management of psoriasis and psoriatic arthritis - Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Drug therapy - Adherence to medication
L Osterberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
分享论文
